Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.36 |
| ▸ | RARB | P10826 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 5/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11933238 | 0.96 | FFAR4 (0.36) | SCN9AFFAR4FFAR1ALOX5APFEN1 | |
| SCHEMBL11933381 | 0.94 | SCN9A (0.36) | SCN9AFFAR4RARBFFAR1PPARD | |
| SCHEMBL15381724 | 0.94 | HPGD (0.38) | SCN9AFFAR4RARBFFAR1ALOX5AP | |
| SCHEMBL11933236 | 0.93 | HPGD (0.39) | FFAR4FFAR1ALOX5APFEN1DGAT1 | |
| SCHEMBL11933380 | 0.90 | FFAR4 (0.36) | SCN9AFFAR4FFAR1PPARDHPGD | |
| SCHEMBL11933374 | 0.89 | SCN9A (0.36) | SCN9AFFAR4RARBALOX5APFEN1 | |
| SCHEMBL11933230 | 0.89 | SCN9A (0.36) | SCN9AFFAR4RARBALOX5APFEN1 | |
| SCHEMBL11933128 | 0.88 | SCN9A (0.36) | SCN9AFFAR4RARBFFAR1ALOX5AP | |
| SCHEMBL15381522 | 0.88 | HPGD (0.42) | FFAR4ALOX5APFEN1DGAT1HPGD | |
| SCHEMBL15381588 | 0.88 | HPGD (0.38) | SCN9AFFAR4RARBPPARDHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580147-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | SCN9A 2717/4885FFAR4 1038/4885RARB 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.